Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ergela Hasa"'
Autor:
Kambiz Rahbar, Markus Essler, Kim M. Pabst, Matthias Eiber, Christian la Fougère, Vikas Prasad, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Wolfgang P. Fendler, Milena Kurtinecz, Anja Schmall, Frank Verholen, Oliver Sartor
Publikováno v:
Journal of Nuclear Medicine. 64:574-578
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c84b508399c995894786db43e7e4e8f
https://doi.org/10.2967/jnumed.122.264456
https://doi.org/10.2967/jnumed.122.264456
Publikováno v:
Der Radiologe. 61:818-824
Das Prostatakarzinom ist die haufigste maligne Erkrankung und die zweithaufigste karzinombedingte Todesursache bei Mannern in Deutschland. Eine sichere Diagnose und ein Staging mit praziser Bildgebung sind entscheidend, um den Patienten eine zielgena
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::57bac851c11758cc2d934fbc27817f32
https://doi.org/10.1007/s00117-021-00895-3
https://doi.org/10.1007/s00117-021-00895-3
Autor:
Kambiz, Rahbar, Markus, Essler, Kim M, Pabst, Matthias, Eiber, Christian Peter, la Fougère, Vikas, Prasad, Philipp, Rassek, Ergela, Hasa, Helmut, Dittmann, Ralph A, Bundschuh, Wolfgang Peter, Fendler, Milena, Kurtinecz, Anja, Schmall, Frank, Verholen, Alton O, Sartor
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
The RAdium LUtetium (RALU) study evaluated the feasibility of sequential alpha and beta emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer.This pre-planned, interim, retrospective analysis investigated safet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fe21c2514cebe95a5ef68841a4a26091
https://pubmed.ncbi.nlm.nih.gov/36302656
https://pubmed.ncbi.nlm.nih.gov/36302656
Autor:
Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Wolfgang P. Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Kim M. Pabst, Milena Kurtinecz, Per Sandstrom, Frank Verholen, A. Oliver Sartor
5040 Background: 223Ra and 177Lu-PSMA both prolong overall survival (OS) in different mCRPC settings. Previous data from the observational REASSURE (Sartor O, et al. 2021) and WARMTH (Ahmadzadehfar H, et al. 2021) studies suggested the feasibility of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67ce6df1b9034afcd3bdf1c8c2057ed0
Autor:
Kambiz Rahbar, Markus Essler, Matthias Eiber, Christian la Fougère, Vikas Prasad, Kim M. Pabst, Wolfgang Peter Fendler, Philipp Rassek, Ergela Hasa, Helmut Dittmann, Ralph A. Bundschuh, Milena Kurtinecz, Anja Schmall, Frank Verholen, A. Oliver Sartor
Publikováno v:
Journal of Clinical Oncology. 41:73-73
73 Background: 223Ra and 177Lu-PSMA-617 both prolong overall survival (OS) in different mCRPC settings. The observational, retrospective study, RALU, investigated safety and clinical outcomes of sequential 223Ra/177Lu-PSMA therapy in patients (pts) w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f456e5a2ec2107f20fbb831185b71840
https://doi.org/10.1200/jco.2023.41.6_suppl.73
https://doi.org/10.1200/jco.2023.41.6_suppl.73
Publikováno v:
Der RadiologeLiteratur. 61(9)
Prostate cancer is the most common malignancy and the second leading cause of cancer-related death in men. Accurate imaging diagnosis and staging are crucial for patient management and treatment. The role of nuclear medicine in the diagnosis of prost
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3e54a09c2a068f264a897e99cd04caae
https://pubmed.ncbi.nlm.nih.gov/34351430
https://pubmed.ncbi.nlm.nih.gov/34351430